A61K31/4166

UNNATURAL AMINO ACIDS AND USES THEREOF
20230042042 · 2023-02-09 ·

This invention provides unnatural amino acids as well as amino acid sequences, foldamers, macrocycles, and formulations comprising said unnatural amino acids. In one aspect of the invention, the unnatural amino acids or the formulation thereof are used to mimic natural amino acids or the formulations thereof in a subject in need thereof.

UNNATURAL AMINO ACIDS AND USES THEREOF
20230042042 · 2023-02-09 ·

This invention provides unnatural amino acids as well as amino acid sequences, foldamers, macrocycles, and formulations comprising said unnatural amino acids. In one aspect of the invention, the unnatural amino acids or the formulation thereof are used to mimic natural amino acids or the formulations thereof in a subject in need thereof.

NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECT AT RISK OF PRETERM DELIVERY
20180003713 · 2018-01-04 ·

Methods for diagnosis to allow prediction of the likelihood of preterm birth based upon the concentration of lipocalin-type prostaglandin D2 synthase (L-PGDS) in cervical vaginal secretions. In addition, specific prostaglandin D2 receptor antagonists may represent novel tocolytic therapeutics.

NON-INVASIVE BIOMARKER TO IDENTIFY SUBJECT AT RISK OF PRETERM DELIVERY
20180003713 · 2018-01-04 ·

Methods for diagnosis to allow prediction of the likelihood of preterm birth based upon the concentration of lipocalin-type prostaglandin D2 synthase (L-PGDS) in cervical vaginal secretions. In addition, specific prostaglandin D2 receptor antagonists may represent novel tocolytic therapeutics.

PRODUCT, OR ACTIVE AGENT, OR COMPOSITION FOR THE CARE OF THE BREASTS IN A PREMENSTRUAL OR MENSTRUAL PERIOD OR FOR THE CARE OF THE SYMPTOMATOLOGY OF MASTODYNIA
20180002281 · 2018-01-04 ·

A method for caring for or treating the breasts during premenstrual or menstrual phases and for the care or treatment of the symptomatology of mastodynia, comprising a step of selecting or identifying women needing care or treatment of the breasts, or suffering from symptomatology of mastodynia, and a step of applying to the skin areas in need thereof an effective amount of a product, active agent or composition, comprising peroxidized lipids or a peroxidised oil, or consisting essentially of peroxidized lipids or of a peroxidised oil.

PRODUCT, OR ACTIVE AGENT, OR COMPOSITION FOR THE CARE OF THE BREASTS IN A PREMENSTRUAL OR MENSTRUAL PERIOD OR FOR THE CARE OF THE SYMPTOMATOLOGY OF MASTODYNIA
20180002281 · 2018-01-04 ·

A method for caring for or treating the breasts during premenstrual or menstrual phases and for the care or treatment of the symptomatology of mastodynia, comprising a step of selecting or identifying women needing care or treatment of the breasts, or suffering from symptomatology of mastodynia, and a step of applying to the skin areas in need thereof an effective amount of a product, active agent or composition, comprising peroxidized lipids or a peroxidised oil, or consisting essentially of peroxidized lipids or of a peroxidised oil.

FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS

Compounds of formula I and their metabolites are potent mediators of an inflammatory response:

##STR00001##

where a, b, c, d, e, f, V, W, X, Y, R.sup.a, R.sup.a′, R.sup.b, R.sup.b′, R.sup.c, and R.sup.c′ are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.

FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS

Compounds of formula I and their metabolites are potent mediators of an inflammatory response:

##STR00001##

where a, b, c, d, e, f, V, W, X, Y, R.sup.a, R.sup.a′, R.sup.b, R.sup.b′, R.sup.c, and R.sup.c′ are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.

OPHTHALMIC COMPOSITIONS

The present invention relates to a sterile ophthalmic composition comprising castor oil and a medium chain triglyceride, to its use in medicine, in particular for the treatment and/or prevention of an ocular disease selected from the group consisting of dry eye, conjunctivitis, dermatitis, blepharitis, entropion, floppy eyelid syndrome, thyroid ophthalmopathy, pterygium, conjunctivochalasis, epithelial damage induced by preservatives, epithelial or anterior chamber damage induced by ocular surgery, limbal cell deficiency, corneal ulcers induced by physical or chemical agents, keratitis, episcleritis and uveitis.

OPHTHALMIC COMPOSITIONS

The present invention relates to a sterile ophthalmic composition comprising castor oil and a medium chain triglyceride, to its use in medicine, in particular for the treatment and/or prevention of an ocular disease selected from the group consisting of dry eye, conjunctivitis, dermatitis, blepharitis, entropion, floppy eyelid syndrome, thyroid ophthalmopathy, pterygium, conjunctivochalasis, epithelial damage induced by preservatives, epithelial or anterior chamber damage induced by ocular surgery, limbal cell deficiency, corneal ulcers induced by physical or chemical agents, keratitis, episcleritis and uveitis.